Synthroid market share "holding steady"

Executive Summary

Synthroid "monthly market share continues to hold steady and market growth remains healthy in the high single digits," Abbott VP-Investor Relations & Public Affairs Catherine Babington said. Third quarter sales were $216 mil., up from $166 mil. in the previous quarter. The levothyroxine product "reported unusually strong third-quarter sales due in part to trade and patient stocking." FDA is requiring Abbott to phase-down its distribution of Synthroid while the NDA, submitted Aug. 1, is pending at the agency (1"The Pink Sheet" July 16, p. 16)